以血小板减少为首发症状的前列腺癌骨髓转移1例报道

doi:10.19558/j.cnki.10-1020/r.2022.02.014

摘要
图/表
参考文献
相关文章 (15)

[1] RAWLA P.Epidemiology of prostate cancer[J]. World J Oncol,2019,10(2):63-89.
[2] HENRICH SE, MCMAHON KM, PLEBANEK MP, et al.Prostate cancer extracellular vesicles mediate intercellular communication with bone marrow cells and promote metastasis in a cholesterol‐dependent manner[J]. J Extracell Vesicles,2020,10(2):e12042.
[3] KARLSSON R, LARSSON P, MIFTAKHOVA R, et al.Establishment of prostate tumor growth and metastasis is supported by bone marrow cells and is mediated by pip5k1α lipid kinase[J]. Cancers,2020,12(9):2719.
[4] WAGASKAR VG, LEVY M, RATNANI P, et al.Clinical utility of negative multiparametric magnetic resonance imaging in the diagnosis of prostate cancer and clinically significant prostate cancer[J]. Eur Urol Open Sci,2021,28:9-16.
[5] LIU YY, DONG L, XIANG LH, et al.Does PSA level affect the choice of prostate puncture methods among MRI-ultrasound fusion targeted biopsy, transrectal ultrasound systematic biopsy or the combination of both[J]? Br J Radiol,2021,94:20210312.
[6] ZHAI LX, ZHANG XJ, GAO YX, et al.Progress in imaging diagnosis and image-guided puncture biopsy of prostate cancer[J]. Adv Ultra Diag Ther,2019,3(4):175-181.
[7] ROSHANI H, ROOS EPM, ELZEVIER HW, et al.Patients and physician satisfaction of Degarelix in androgen deprivation therapy for advanced hormone-dependent prostate cancer in the Netherlands[J]. Curr Urol,2021,15(4):204-208.
[8] SAWAZAKI H, ARAKI D, KITAMURA Y, et al.Metabolic changes with degarelix vs leuprolide plus bicalutamide in patients with prostate cancer: a randomized clinical study[J]. World J Urol,2020,38(6):1465-1471.
[9] RATHKOPF DE, SCHER HI.Apalutamide for the treatment of prostate cancer[J]. Expert Rev Anticancer Ther,2018,18(9):823-836.
[10] DELLIS AE, PAPATSORIS AG.Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer[J]. Expert Opin Investig Drugs,2018,27(6):553-559.
[11] MCBRIDE SM, ZELEFSKY MJ, KOLLMEIER M, et al.Interim results of aasur: a single arm, multi-center phase 2 trial of apalutamide (A)+ abiraterone acetate+ prednisone (AA+ P)+ leuprolide with stereotactic ultra-hypofractionated radiation (UHRT) in very high risk (VHR), node negative (N0) prostate cancer (PCa)[J]. J Clin Oncol,2021,39(15 Suppl):5012.